Phaseline

Targets › ASPG

ASPG (60 kDa lysophospholipase): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 1 Phase 3, 1 Phase 4, 1 Phase 1; Oncology; next expected readout Nov 2026.

Exhibits lysophospholipase, transacylase, PAF acetylhydrolase and asparaginase activities (By similarity). Can catalyze three types of transacylation reactions: (1) acyl transfer from 1-acyl-sn-glycero-3-phosphocholine (1-acyl-GPC) to the sn-1(3) positions of glycerol and 2-acylglycerol (sn-1 to -1(3) transfer), (2) acyl transfer from 1-acyl-GPC to the sn-2 positions of 1-acyl-GPC,…. (UniProt, Q86U10)

Open in Phaseline: the race on ASPG, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Wei ZhaoPegaspargase
Asparaginase depleting enzyme
ASPGPhase 4Hematological NeoplasmsDec 2026
Dana-Farber Cancer InstitutePegaspargase
L-asparaginase pegylated conjugate; depletes asparagine to inhibit protein synthesis in le
ASPGPhase 3Acute Lymphoblastic Leukemia, PediatricNov 2026
West Virginia UniversityCalaspargase pegol-mknl
Asparaginase - depletes asparagine for leukemic blast cells
ASPGPhase 1Acute Myeloid LeukemiaFeb 2030

Conditions

Acute Lymphoblastic Leukemia, Pediatric (1) Hematological Neoplasms (1) Acute Myeloid Leukemia (1)

Modalities

mixed (2), protein or peptide (1)

Companies

Dana-Farber Cancer Institute (1) Wei Zhao (1) West Virginia University (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.